Skip to content

Released Nov 13, 2023, after the close

10-Q filed Nov 13, 2023, 44 days after period end · 0000950170-23-062897

Q3 2023 · 10-Q
Revenue$218.00K−79.9% vs Q3 2022−19.0% vs Q2 2023
Net Income-$3.20MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.06N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$1,934,000N/M
Operating Cash Flowderived$15,915,000N/M
Margins · derived
Operating margin-887.2%+206.6 pt vs Q3 2022
Net margin-1467.9%−386.6 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$218.00K$1.08M$708.00K$38.00K
Net Income-$3.20M-$11.70M-$22.50M-$18.90M
EPS Diluted-$0.06-$0.33-$0.70-$0.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR